Epidemiology of hyperkalemia: An update

Kidney International Supplements

Volumn 6, Issue 1, 2016, Pages 3-6

  Kovesdy, Csaba P ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

chronic kidney disease; epidemiology; hyperkalemia; mortality

Indexed keywords

EID: 84964414231     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1016/j.kisu.2016.01.002     Document Type: Review

References (42)

1. J.L. Fleet, S.Z. Shariff, S. Gandhi, and et al. Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission BMJ Open 2 2012 e002011
2. L.M. Einhorn, M. Zhan, V.D. Hsu, and et al. The frequency of hyperkalemia and its significance in chronic kidney disease Arch Intern Med 169 2009 1156 1162
3. P.E. Drawz, D.C. Babineau, and M. Rahman Metabolic complications in elderly adults with chronic kidney disease J Am Geriatr Soc 60 2012 310 315
4. P.A. Sarafidis, R. Blacklock, E. Wood, and et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic Clin J Am Soc Nephrol 7 2012 1234 1241
5. J. Hayes, K. Kalantar-Zadeh, J.L. Lu, and et al. Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race Nephron Clin Pract 120 2012 c8 c16
6. C.P. Kovesdy, D.L. Regidor, R. Mehrotra, and et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients Clin J Am Soc Nephrol 2 2007 999 1007
7. B.F. Palmer Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system N Engl J Med 351 2004 585 592
8. C.P. Kovesdy Management of hyperkalaemia in chronic kidney disease Nat Rev Nephrol 10 2014 653 662
9. C.P. Kovesdy Management of hyperkalemia: an update for the internist Am J Med 128 2015 1281 1287
10. G.A. Knoll, A. Sahgal, R.C. Nair, and et al. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients Am J Med 112 2002 110 114
11. J.M. Weinberg, L.J. Appel, G. Bakris, and et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy Arch Intern Med 169 2009 1587 1594
12. Y. Iino, M. Hayashi, T. Kawamura, and et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study Hypertens Res 27 2004 21 30
13. Y. Miao, D. Dobre, H.J. Heerspink, and et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial Diabetologia 54 2011 44 50
14. L.F. Fried, N. Emanuele, J.H. Zhang, and et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy N Engl J Med 369 2013 1892 1903
15. Avapro package insert. Available at: http://products.sanofi.us/Avapro/Avapro.pdf. Accessed September 10, 2015.
16. E.J. Lewis, L.G. Hunsicker, R.P. Bain, and et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N Engl J Med 329 1993 1456 1462
17. G. Maschio, D. Alberti, G. Janin, and et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group N Engl J Med 334 1996 939 945
18. P. Ruggenenti, A. Perna, G. Loriga, and et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial Lancet 365 2005 939 946
19. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Lancet 349 1997 1857 1863
20. F.F. Hou, X. Zhang, G.H. Zhang, and et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency N Engl J Med 354 2006 131 140
21. J.F. Mann, H.C. Gerstein, J. Pogue, and et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Ann Intern Med 134 2001 629 636
22. H. Makani, S. Bangalore, K.A. Desouza, and et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials BMJ 346 2013 f360
23. P. Susantitaphong, K. Sewaralthahab, E.M. Balk, and et al. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis Am J Hypertens 26 2013 424 441
24. B. Bozkurt, I. Agoston, and A.A. Knowlton Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines J Am Coll Cardiol 41 2003 211 214
25. K.B. Shah, K. Rao, R. Sawyer, and et al. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure J Am Coll Cardiol 46 2005 845 849
26. A. Goyal, J.A. Spertus, K. Gosch, and et al. Serum potassium levels and mortality in acute myocardial infarction JAMA 307 2012 157 164
27. S. Korgaonkar, A. Tilea, B.W. Gillespie, and et al. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study Clin J Am Soc Nephrol 5 2010 762 769
28. A.J. Collins, N. Reaven, S. Funk, and et al. Potassium levels and mortality in patients with CKD [abstract] J Am Soc Nephrol 25 2014 270A
29. E.G. Lowrie, and N.L. Lew Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities Am J Kidney Dis 15 1990 458 482
30. K. Iseki, H. Uehara, K. Nishime, and et al. Impact of the initial levels of laboratory variables on survival in chronic dialysis patients Am J Kidney Dis 28 1996 541 548
31. Q. Xu, F. Xu, L. Fan, and et al. Serum potassium levels and its variability in incident peritoneal dialysis patients: associations with mortality PLoS One 9 2014 e86750
32. F.H. Epstein Signs and symptoms of electrolyte disorders M.H. Maxwell, C.R. Kleeman, Clinical Disorders of Fluid and Electrolyte Metabolism 3rd ed 1980 McGraw-Hill New York, NY 499 516
33. C. Fisch Electrolytes and the heart J.W. Hurst, The Heart 5th ed 1982 McGraw-Hill New York, NY 1599 1612
34. E. Yetkin, M. Ileri, I. Tandogan, and et al. Increased QT interval dispersion after hemodialysis: role of peridialytic electrolyte gradients Angiology 51 2000 499 504
35. S.E. Nappi, V.K. Virtanen, H.H. Saha, and et al. QTc dispersion increases during hemodialysis with low-calcium dialysate Kidney Int 57 2000 2117 2122
36. J.O. Burton, S. Korsheed, B.J. Grundy, and et al. Hemodialysis-induced left ventricular dysfunction is associated with an increase in ventricular arrhythmias Ren Fail 30 2008 701 709
37. L. Voroneanu, and A. Covic Arrhythmias in hemodialysis patients J Nephrol 22 2009 716 725
38. N.M. Selby, and C.W. McIntyre The acute cardiac effects of dialysis Semin Dial 20 2007 220 228
39. J.E. Miller, C.P. Kovesdy, K.C. Norris, and et al. Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients Am J Nephrol 32 2010 403 413
40. L. Li, E. Streja, C.M. Rhee, and et al. Hypomagnesemia and mortality in incident hemodialysis patients Am J Kidney Dis 66 2015 1047 1055
41. P.H. Pun, R.W. Lehrich, E.F. Honeycutt, and et al. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics Kidney Int 79 2011 218 227
42. M. Jadoul, J. Thumma, D.S. Fuller, and et al. Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study Clin J Am Soc Nephrol 7 2012 765 774